Newsfeeds - Spark Newswire

1 minute read

Canaccord Genuity Initiates Coverage On Pacific Biosciences with Buy Rating, Announces Price Target of $45

Today, 7:52 AM

Canaccord Genuity analyst Kyle Mikson initiates coverage on Pacific Biosciences (NASDAQ:PACB) with a Buy rating and announces Price Target of $45.

PACB

3 minute read

5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More

By Chris Katje

Today, 7:52 AM

Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this happened globally and in the U.S.

AAPL

1 minute read

Pacific Biosciences Wins $664K Contract Titled ‘Delivery Order issued under USDA Indefinite Delivery Indefinite Quantity (IDIQ) Contract # 12405B21D0002 with Pacific Biosciences of California’

By Benzinga Newsdesk

Today, 7:52 AM

https://sam.gov/opp/c67143caddf245a4ae4d11611987bd82/view

PACB

1 minute read

Billionaire Masayoshi Son’s SoftBank Claims $5B Stake In Roche: Bloomberg

By Vandana Singh

Today, 7:52 AM

SoftBank Group Corp (OTC:SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC:RHHBF), making it one of the…

ABCL

1 minute read

Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $41

By Benzinga Newsdesk

Today, 7:52 AM

Morgan Stanley analyst Tejas Savant maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target from $45 to $41.

PACB

1 minute read

Pacific Biosciences Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $30.60M Beat $29.89M Estimate

By Benzinga Newsdesk

Today, 7:52 AM

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 40 percent decrease over losses of $(0.15) per share from

PACB

21 minute read

Earnings Scheduled For August 3, 2021

By Benzinga Insights

Today, 7:52 AM

Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.

AAIC

1 minute read

Pacific Biosciences To Buy DNA Sequencing Firm For Up To $800M, Announces $300M Capital Raise For Deal Funding

By Vandana Singh

Today, 7:52 AM

Pacific Biosciences of California Inc (NASDAQ:PACB) has agreed to acquire Omniome, a San Diego-based company developing a short-read sequencing platform. …

NVTA

2 minute read

News

Pacific Biosciences Of California Reports Expansion Of Collaboration With Invitae

By Benzinga Newsdesk

Today, 7:52 AM

Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc. Combining both highly accurate long and short read sequencing technologies expected to provide deeper

NVTA

3 minute read

Pacific Biosciences Of California Reports Purchase Of Omniome For $300M In Cash Plus Added $200M In Cash, Stock Payable Related To Certain Milestones

By Benzinga Newsdesk

Today, 7:52 AM

Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets Brings together Omniome’s high accuracy short-read sequencing

PACB